Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594815 · ClinicalTrials.gov registry record · NA
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT00594815: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00594815 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00594815, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor. It is usually treated with chemotherapy and radiation. This combination prolongs survival, but about half of patients relapse. The investigators hope that the addition of rituximab will improve the control of the tumor.
Interventions
- DRUG Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2002-08-28 |
| Est. Completion | 2016-02-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00594815
The ClinicalTrials.gov registry entry for NCT00594815 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine is the first listed.
NCT00594815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00594815 about?
NCT00594815 is a clinical study titled "Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma". The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor. It is usually treated with chemotherapy and radiation. This combination prolongs survival, but about half of pat...
What is the current status of trial NCT00594815?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2002-08-28. Estimated completion is 2016-02-23.
What interventions are being tested in trial NCT00594815?
The interventions under investigation include: Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine (DRUG).
Who is sponsoring clinical trial NCT00594815?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.